Spotlight on New Oncology Drugs: Access, Costs, and Use

Slideshow

Read compelling analyses of 5-year trends and projected changes in the oncology clinical drug pipeline, selected from the IMS Institute for Healthcare Informatics’ recent “Global Oncology Trend Report.”

Slides republished with permission from the IMS Institute for Healthcare Informatics. Visit theimsinstitute.org to view the full publication, “Global Oncology Trend Report: A Review of 2015 and Outlook to 2020.”

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content
Data from DeLLphi-304 support tarlatamab as a preferable second-line therapy for patients with small cell lung cancer.

Second-Line Tarlatamab Improves PFS, OS in Small Cell Lung Cancer

Chris Ryan
June 5th 2025
Article

Data from DeLLphi-304 support tarlatamab as a preferable second-line therapy for patients with small cell lung cancer.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

High Response Rates Seen with Fruquintinib Combo in HER2– Advanced Gastric/GEJ Cancer

High Response Rates Seen with Fruquintinib Combo in HER2– Advanced Gastric/GEJ Cancer

Kyle Doherty
June 4th 2025
Article

Fruquintinib plus chemotherapy and a PD-1 inhibitor elicited an ORR of 80.0% with all partial responses in patients with treatment-naïve gastric/GEJ cancer.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.

An International Search for Lung Cancer Treatment Leads to Double Lung Transplant

Roman Fabbricatore
June 4th 2025
Article

The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.

Investigators of the OVATION-2 trial assessed IMNN-001, a novel IL-2 gene therapy, in patients with newly diagnosed epithelial ovarian cancer.

PFS, OS Numerically Improve Via IMNN-001 Combo in Epithelial Ovarian Cancer

Chris Ryan
June 4th 2025
Article

Investigators of the OVATION-2 trial assessed IMNN-001, a novel IL-2 gene therapy, in patients with newly diagnosed epithelial ovarian cancer.